Quality of cancer screening programmes
Several European countries have implemented cancer prevention programmes for colorectal cancer either with a fecal test or a colonoscopy screening test. Quality of colonoscopy is considered important for both schemes. The goal of the ACCEPT study is to understand how implementation of AI can change the quality of colorectal cancer screening programmes. Approximately 220 000 participants who undergo colonoscopy under cancer screening programmes in Europe and Japan will be included. Participants are assigned to colonoscopy with or without the use of AI for polyp detection. The short-term primary endpoints are the detection rates of adenomas and advanced adenomas, while the long-term primary endpoints are colorectal cancer incidence and mortality after long-term follow-up.
Status of the ACCEPT trial
Inclusion of the ACCEPT trial started in November 2021 with a first participant at Radom in Poland. The study has spread to Poland, Spain, Italy, Denmark, Sweden, and Japan. As of April 2024 the number of participants reached 10 000. As new clinics and hospitals in Europe are being recruited to join the trial, the inclusion number is increasing exponentially.
– This is very good news, and the inclusion speed is satisfying, says Yuichi Mori, professor at the University of Oslo and the OperA project coordinator.
– The ACCEPT trial is an ambitious endeavour and output of great friendship and international collaboration. It wouldn't be possible without all our partners and colleagues in Europe and Japan who I think are the main players in this contribution. Including 10 000 participants in the first period of the project is a great landmark, and we will celebrate it with our teams.
Learn more about the OperA project, the ACCEPT trial, and the Clinical Effectiveness Research Group.